{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:25:47Z","timestamp":1761989147572},"reference-count":61,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2018,3,30]],"date-time":"2018-03-30T00:00:00Z","timestamp":1522368000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Basic Clin Pharma Tox"],"published-print":{"date-parts":[[2018,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Faldaprevir (FDV) is a potent, orally administered inhibitor of hepatitis C virus. In this single\u2010centre, open\u2010label, fixed\u2010sequence, crossover study of 32 healthy adult male and female volunteers, subjects received either a single dose of cyclosporine (CsA) 50 mg (N = 16) or tacrolimus (TAC) 0.5 mg (N = 16), followed by a washout of at least 14 days. Each subject then received a loading dose of FDV 240 mg followed by 120 mg FDV once daily for 6 days. FDV 120 mg was then co\u2010administered with an additional single dose of CsA (50 mg) or TAC (0.5 mg), followed by an additional 6 days of FDV 120 mg once daily. Intensive blood sampling was performed to assess the PK interaction potential. Assessment of relative BA indicated that exposure to CsA co\u2010administered with FDV was similar to CsA alone. However, the AUC<jats:sub>\u03c4,ss<\/jats:sub>and<jats:italic>C<\/jats:italic><jats:sub>max,ss<\/jats:sub>of FDV were increased by 23% and 41%, respectively, when FDV was co\u2010administered with CsA. Exposure to TAC was slightly increased (AUC<jats:sub>0\u2010\u221e<\/jats:sub>increased by 27%, no change in<jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub>) when TAC was co\u2010administered with FDV. In contrast, exposure to FDV co\u2010administered with TAC was similar to FDV alone. No unexpected safety findings arose from the trial. The limitations of the study (use of single, low dose of TAC and CsA, and only healthy volunteers in the trial) are discussed.<\/jats:p>","DOI":"10.1111\/bcpt.12980","type":"journal-article","created":{"date-parts":[[2018,2,10]],"date-time":"2018-02-10T09:02:40Z","timestamp":1518253360000},"page":"84-93","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pharmacokinetic Interaction between Faldaprevir and Cyclosporine or Tacrolimus in Healthy Volunteers: A Prospective, Open\u2010Label, Fixed\u2010Sequence, Crossover Study"],"prefix":"10.1111","volume":"123","author":[{"given":"Fenglei","family":"Huang","sequence":"first","affiliation":[{"name":"Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield CT USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Voelk","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharma GmbH &amp; Co. KG Biberach Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Trampisch","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharma GmbH &amp; Co. KG Ingelheim Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lois","family":"Rowland","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield CT USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armin","family":"Schultz","sequence":"additional","affiliation":[{"name":"CRS Clinical Research Services Mannheim GmbH Mannheim Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John P.","family":"Sabo","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield CT USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,3,30]]},"reference":[{"key":"e_1_2_7_2_1","first-page":"304","article-title":"Recurrence of hepatitis C after liver transplantation","volume":"26","author":"Vinaixa C","year":"2013","journal-title":"Ann Gastroenterol"},{"key":"e_1_2_7_3_1","unstructured":"Trek Therapeutics P.A study of faldaprevir ribavirin and TD\u20106450 in participants with genotype 4 hepatitis C virus infection2017;http:\/\/clinicaltrials.gov\/show\/NCT02593162(last accessed on 5 January 2018)."},{"key":"e_1_2_7_4_1","unstructured":"Trek Therapeutics P.A study of faldaprevir TD\u20106450 and other antivirals in participants with genotype 1b hepatitis C virus infection. 2017;http:\/\/clinicaltrials.gov\/show\/NCT02716428(last accessed on 5 January 2018)."},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00787-10"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.12.024"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26386"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26276"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1213557"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2567"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.08.040"},{"key":"e_1_2_7_12_1","unstructured":"SennewaldR NarjesN YongCL NehmizN HuangF SternJO.Safety tolerability and pharmacokinetics of faldaprevir after single rising doses in healthy subjects. 2014 American Society for Clinical Pharmacology and Therapeutics (ASCPT) Annual Meeting March 18\u201022 2014 Atlanta GA. Poster # PII\u2010025; 2014."},{"key":"e_1_2_7_13_1","unstructured":"HuangF HaertterS QuinsonAM.Effect of intrinsic factors on the exposure of faldaprevir in HCV\u2010infected patients: pooled analysis of data from three faldaprevir phase 3 studies. 2016 Annual American College of Clinical Pharmacology Meeting Bethesda MD. 25\u201027 September 2016. Poster 17;2016."},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/jphp.12538"},{"key":"e_1_2_7_15_1","first-page":"730A","article-title":"Pharmacokinetic interactions of faldaprevir and deleobuvir (BI 207127) and their individual and combined effects on selected cytochrome p450 (CYP) probe substrates in genotype 1 hepatitis C infected patients","volume":"58","author":"Cooper C","year":"2013","journal-title":"Hepatology"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu616"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24443"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25831"},{"key":"e_1_2_7_19_1","unstructured":"Janssen.OLYSIO [package insert].Janssen Therapeutics Division of Janssen Products LP Titusville NJ 2017."},{"key":"e_1_2_7_20_1","unstructured":"AbbVie.VIEKIRA PAK (ombitasvir paritaprevir and ritonavir tablets; dasabuvir tablets) [package insert].AbbVie Inc. North Chicago IL 2014."},{"key":"e_1_2_7_21_1","unstructured":"Merck.ZEPATIER (elbasvir and grazoprevir) [package insert].Merck & Co. Inc. Whitehouse Station NJ 2016."},{"key":"e_1_2_7_22_1","unstructured":"Schering.VICTRELIS [package insert].Schering Corporation a subsidiary of MERCK & CO. INC. Whitehouse Station NJ 2011."},{"key":"e_1_2_7_23_1","unstructured":"Vertex.INCIVEK [package insert].Vertex Pharmaceuticals Incorporated Cambridge MA 2012."},{"key":"e_1_2_7_24_1","unstructured":"Novartis.NEORAL [package insert].Novartis Pharmaceuticals Corporation East Hanover NJ 2015."},{"key":"e_1_2_7_25_1","unstructured":"Astellas.PROGRAF [package insert].Astellas Pharma US Inc. Northbrook IL 2015."},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24470"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03359-14"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04046-14"},{"key":"e_1_2_7_29_1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/00031305.1989.10475628","article-title":"How appropriate are popular sample size formulas?","volume":"42","author":"Kupper LL","year":"1989","journal-title":"Am Stat"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2005.08.004"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270006296523"},{"key":"e_1_2_7_32_1","unstructured":"US Food and Drug Administration.Guidance for industry: drug interaction studies\u2014study design data analysis implications for dosing and labeling recommendations.2012."},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-013-0097-y"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12377"},{"key":"e_1_2_7_35_1","unstructured":"MarzinK KoenenR StrelkowaN KammererK\u2010P ElgadiM HuangF.Pharmacokinetics of faldaprevir in healthy subjects following co\u2010administration with itraconazole 2014 European Association for Study of Liver (EASL) Annual Meeting London UK. 09\u201013 April 2014; 2014."},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2008.168"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0b013e31817b5b5a"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.104.002931"},{"key":"e_1_2_7_39_1","unstructured":"NelsonM ArastehK JainMK SorianoV MadrugaJ FurtadoJet al. (eds).Effect of faldaprevir on atazanavir pharmacokinetics in patients with HIV\/HCV co\u2010infection. 2014 Conference On Retroviruses And Opportunistic Infections (CROI) Boston MA. 3\u20106 March 2014;2014."},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.108.023648"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2012.163"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.113.055863"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.113.055897"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02156-13"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.525"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.142"},{"key":"e_1_2_7_47_1","unstructured":"US Food and Drug Administration.Simeprevir: clinical pharmacology and biopharmaceutics review 2013;http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2013\/205123Orig1s000ClinPharmR.pdf"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050093"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1992.tb03845.x"},{"key":"e_1_2_7_50_1","first-page":"108","article-title":"Digoxin\u2010cyclosporine interaction: severe digitalis toxicity after cyclosporine treatment","volume":"11","author":"Dorian P","year":"1988","journal-title":"Clin Invest Med"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2005.01005.x"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200241110-00003"},{"key":"e_1_2_7_53_1","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1097\/QAD.0000000000000579","article-title":"STARTVerso4: faldaprevir and pegylated interferon alpha\u20102a\/ribavirin in individuals co\u2010infected with hepatitis C virus genotype\u20101 and HIV","volume":"29","author":"Dieterich D","year":"2015","journal-title":"AIDS"},{"key":"e_1_2_7_54_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.436"},{"key":"e_1_2_7_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-003-1034-7"},{"key":"e_1_2_7_56_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-006-0133-z"},{"key":"e_1_2_7_57_1","unstructured":"AbbVie.MAVYRET (glecaprevir and pibrentasvir) tablets [package insert].AbbVie Inc. North Chicago IL 2017."},{"key":"e_1_2_7_58_1","unstructured":"Gilead.VOSEVI (sofosbuvir velpatasvir and voxilaprevir) tablets [package insert].Gilead Sciences Inc. Foster City CA 2017."},{"key":"e_1_2_7_59_1","doi-asserted-by":"publisher","DOI":"10.1002\/lt.21387"},{"key":"e_1_2_7_60_1","doi-asserted-by":"publisher","DOI":"10.1002\/lt.20627"},{"key":"e_1_2_7_61_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.114.218081"},{"key":"e_1_2_7_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12424"}],"container-title":["Basic &amp; Clinical Pharmacology &amp; Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcpt.12980","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcpt.12980","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T03:31:37Z","timestamp":1719804697000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bcpt.12980"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,30]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["10.1111\/bcpt.12980"],"URL":"https:\/\/doi.org\/10.1111\/bcpt.12980","archive":["Portico"],"relation":{},"ISSN":["1742-7835","1742-7843"],"issn-type":[{"value":"1742-7835","type":"print"},{"value":"1742-7843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,30]]},"assertion":[{"value":"2017-09-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-01-31","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-03-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}